NEW YORK, July 26 - Dutch pharmaceutical company Organon had agreed to renew and expand its subscription to Lexicon’s OmniBank library and DNA sequence database, Lexicon Genetics said Thursday.

Under the terms of the deal, Oragnon will have access to Lexicon’s tools through December 2002. In addition, Organon will also have access to Lexicon’s gene knockouts as well as to drug target validation data generated by Lexicon for specified targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.